Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6042192 | 0.89 | ALDH1A1 (0.49) | ALDH1A1MAPK1MTNR1AMTNR1BTSHR | |
| SCHEMBL23015062 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK1MTNR1AMTNR1BTSHR | |
| SCHEMBL9647380 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPK1MTNR1AMTNR1BTSHR | |
| SCHEMBL4614675 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPK1TSHRLMNAKDM4E | |
| SCHEMBL25986916 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MAPK1MTNR1AMTNR1BTSHR | |
| SCHEMBL10744128 | 0.75 | KIF11 (0.54) | — | |
| SCHEMBL1025612 | 0.73 | ALDH1A1 (0.64) | ALDH1A1MAPK1MTNR1AMTNR1BTSHR | |
| SCHEMBL6589802 | 0.72 | CA1 (0.66) | ALDH1A1TSHRLMNAKDM4EUSP2 | |
| SCHEMBL16586149 | 0.72 | ALDH1A1 (0.70) | ALDH1A1MAPK1MTNR1AMTNR1BKDM4E | |
| SCHEMBL7917142 | 0.72 | ALDH1A1 (0.50) | ALDH1A1MAPK1MTNR1AMTNR1BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078123-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI DAIDAI INVESTMENT CONSULTING CO., LTD (CN) | 2026-03-19 | — | — | US | disclosed |
| US-12516054-B2 | Pyrazolo[1,5-a]pyridine derivatives, preparation method therefor and use thereof | SHANGHAI DAIDAI INVESTMENT CONSULTING CO., LTD (CN) | 2026-01-06 | — | — | US | disclosed |
| US-20220135560-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | CLUES THERAPEUTICS (SHANGHAI) LTD (CN) | 2022-05-05 | — | — | US | disclosed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | disclosed |
| US-3993768-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078123-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | NR3C1, CXCR1, CCR1 | ALDH1A1 2581/4885MAPK1 699/4885MTNR1A 506/4885 |
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | ALDH1A1 412/4885MAPK1 2145/4885MTNR1A 37/4885 |
| US-20220135560-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | RET, RIN1, WEE1 | ALDH1A1 1030/4885MAPK1 46/4885MTNR1A 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.